Altimmune: Don't Buy The GLP-1 Move-Up

Akero Therapeutics: Deceptively Promising

POINT Biopharma Global: Why The Market Believes That A Second Bidder May Emerge

Why I Am Selling Aldeyra Therapeutics: A Sour AbbVie Deal And A Lack Of Transparency

Xenon Pharmaceuticals: Upcoming Phase Two Major Depressive Disorder Data Readout Represents An Opportunity

Madrigal Pharmaceuticals: The NASH Market Is No Longer Guaranteed

Terns Pharmaceuticals: Upcoming Obesity Data Is One Of Many Catalysts Coming Up

Why I Am Staying Away From Hepion Pharmaceuticals

Intercept Pharmaceuticals: Do Not Expect PBC Sales To Save The Company

Buy Seagen Now For An Attractive M&A Arbitrage Opportunity

Third Harmonic Bio: A Rabbit Out Of The Hat?

Madrigal Pharmaceuticals Is Still Undervalued After Resmetirom's Phase 3 Success

Intercept Pharmaceuticals: Too Risky To Buy At This Stage

F-star Therapeutics: A Merger Arbitrage Opportunity Expected To Close Soon

It Can Still Get Worse For Canopy Growth

Why I'm Staying Away From Affinia Therapeutics' IPO For Now

Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap